Mast cell sarcoma: A rare and aggressive entity-report of two cases and review of the literature

Journal of Clinical Oncology

Volumn 31, Issue 6, 2013, Pages

  Grandpeix Guyodo, Catherine ^a   Damaj, Gandhi ^a   Barete, Stéphane ^b   Aouba, Achille ^c   Fite, Charlotte ^d   Robert, Caroline ^d   Gaulard, Philippe ^e   Lortholary, Olivier ^c   Tournilhac, Olivier ^f   Dubreuil, Patrice ^g   Hermine, Olivier ^c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f UNIVERSITÉ CLERMONT AUVERGNE   (France)

^g AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; FLUORODEOXYGLUCOSE F 18; STEM CELL FACTOR RECEPTOR; TRYPTASE;

ADULT; ARTICLE; ASCITES; ASTHENIA; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; CELL INFILTRATION; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEVER; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; LYMPHADENOPATHY; MALE; NIGHT SWEAT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RASH; SARCOMA; SKIN BIOPSY; SPLENECTOMY; SPLENOMEGALY; TREATMENT RESPONSE; TUMOR DIAGNOSIS;

ADULT; ANTIGENS, CD30; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FATAL OUTCOME; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MAST CELLS; MAST-CELL SARCOMA; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84875732431     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.41.9549     Document Type: Article

References (28)

1. Horny HP, Parwaresch MR, Lennert K: Bone marrow findings in systemic mastocytosis. Hum Pathol 16:808-814, 1985 (Pubitemid 15040816)
2. Lennert K, Parwaresch MR: Mast cells and mast cell neoplasia: A review. Histopathology 3:349-365, 1979 (Pubitemid 9249267)
3. Metcalfe DD: Classification and diagnosis of mastocytosis: Current status. J Invest Dermatol 96:2S-4S; discussion 4S, 60S-65S, 1991 (3 suppl)
4. Valent P: Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr 108:385-397, 1996 (Pubitemid 26229031)
5. Valent P, Horny HP, Escribano L, et al: Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk Res 25:603-625, 2001 (Pubitemid 32506768)
6. Guenther PP, Huebner A, Sobottka SB, et al: Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. J Pediatr Hematol Oncol 23:134-138, 2001 (Pubitemid 32162678)
7. Horny HP, Parwaresch MR, Kaiserling E, et al: Mast cell sarcoma of the larynx. J Clin Pathol 39:596-602, 1986 (Pubitemid 16069663)
8. Kojima M, Nakamura S, Itoh H, et al: Mast cell sarcoma with tissue eosinophilia arising in the ascending colon. Mod Pathol 12:739-743, 1999 (Pubitemid 29354889)
9. Parwaresch MR, Horny HP, Lennert K: Tissue mast cells in health and disease. Pathol Res Pract 179:439-461, 1985 (Pubitemid 15103249)
10. Brcić L, Vuletić LB, Stepan J, et al: Mast-cell sarcoma of the tibia. J Clin Pathol 60:424-425, 2007 (Pubitemid 46596565)
11. Chott A, Guenther P, Huebner A, et al: Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol 27:1013-1019, 2003 (Pubitemid 36758906)
12. Sotlar K, Horny HP, Lebherz J, et al: Association of bone marrow mastocytosis with extremely immature extramedullary mast cell sarcoma (in German). Pathologe 18:252-256, 1997 (Pubitemid 27267285)
13. Georgin-Lavialle S, Lhermitte L, Baude C, et al: Blood CD34-c-Kit- cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor. Blood 118:5246-5249, 2011
14. Escribano L, Diaz-Agustin B, Lopez A, et al: Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom 58:1-8, 2004 (Pubitemid 38332714)
15. Orfao A, Escribano L, Villarrubia J, et al: Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: Identification and enumeration. Am J Pathol 149:1493-1499, 1996 (Pubitemid 26363956)
16. Sánchez-Munoz L, Teodó sio C, Morgado JM, et al: Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders. Methods Cell Biol 103:333-359, 2011
17. Krauth MT, Fodinger M, Rebuzzi L, et al: Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens. Haematologica 92:e126-e129, 2007
18. Horny HP, Sotlar K, Valent P: Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: A review. Pathobiology 77:169-180, 2010
19. Maric I, Calvo KR: Mastocytosis: The new differential diagnosis of CD30- positive neoplasms. Leuk Lymphoma 52:732-733, 2011
20. Sotlar K, Cerny-Reiterer S, Petat-Dutter K, et al: Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol 24:585- 595, 2011
21. Valent P, Sotlar K, Horny HP: Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: A differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk Lymphoma 52:740-744, 2011
22. Ustun C, DeRemer DL, Akin C: Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 35:1143-1152, 2011
23. Hahn KA, Ogilvie G, Rusk T, et al: Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 22:1301-1309, 2008
24. Aichberger KJ, Sperr WR, Gleixner KV, et al: Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest 38:869-873, 2008
25. Anastassiadis T, Deacon SW, Devarajan K, et al: Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 29:1039-1045, 2011
26. Bohm A, Sonneck K, Gleixner KV, et al: In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol 38:744-755, 2010
27. Gleixner KV, Mayerhofer M, Cerny-Reiterer S, et al: KIT-D816Vindependent oncogenic signaling in neoplastic cells in systemic mastocytosis: Role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 118:1885-1898, 2011
28. Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821, 2010